生物活性分子抑制剂(-)-Indolactam V(Synonyms: Indolactam V)

生物活性分子抑制剂 特异性抑制剂 激动剂 化合物库 重组蛋白 (-)-Indolactam V (Synonyms: Indolactam V) 纯度: 98.63%

(-)-Indolactam V 是 PKC 的激活剂,对 η-CRD2 (PKCη 代替肽),γ-CRD2 (PKCγ 代替肽) 的 Ki 值分别为 3.36 nM 和 1.03 μM,对 PKC C1A 和 C1B 结构域的 Kd 值分别为 5.5 nM (η-C1B),7.7 nM (ε-C1B),8.3 nM (δ-C1B),18.9 nM (β-C1A-long),20.8 nM (α-C1A-long),137 nM (β-C1B),138 nM (γ-C1A) 和 213 nM (γ-C1B),具有抗肿瘤活性。

(-)-Indolactam V(Synonyms: Indolactam V)

(-)-Indolactam V Chemical Structure

CAS No. : 90365-57-4

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥4376 In-stock
1 mg ¥1800 In-stock
5 mg ¥6600 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

(-)-Indolactam V 相关产品

相关化合物库:

  • Bioactive Compound Library Plus

生物活性

(-)-Indolactam V is a PKC activator, with Kis of 3.36 nM, 1.03 μM for η-CRD2 (PKCη surrogate peptide), γ-CRD2 (PKCγ surrogate peptide), and Kds of 5.5 nM (η-C1B), 7.7 nM (ε-C1B), 8.3 nM (δ-C1B), 18.9 nM (β-C1A-long), 20.8 nM (α-C1A-long), 137 nM (β-C1B), 138 nM (γ-C1A), 213 nM (γ-C1B), and has antitumor activity.

IC50 & Target[1][2]

PKCη-CRD2

3.36 nM (Ki)

PKCη-C1B

5.5 nM (Kd)

PKCε-C1B

7.7 nM (Kd)

PKCδ-C1B

8.3 nM (Kd)

PKCθ-C1B

8.7 nM (Kd)

PKCβ-C1A-long

18.9 nM (Kd)

PKCα-C1A-long

20.8 nM (Kd)

PKCβ-C1B

137 nM (Kd)

PKCγ-C1A

138 nM (Kd)

PKCγ-C1B

213 nM (Kd)

PKCγ-CRD2

1030 nM (Ki)

PKCδ-C1A

1900 nM (Kd)

PKCη-C1A

3770 nM (Kd)

PKCα-C1B-long

4000 nM (Kd)

PKCε-C1A

4110 nM (Kd)

体外研究
(In Vitro)

(-)-Indolactam V is a PKC activator, with Kis of 3.36 nM, 1.03 μM for η-CRD2 (PKCη surrogate peptide), γ-CRD2 (PKCγ surrogate peptide), and has antitumor activity[1]. (-)-Indolactam V shows Kds of 5.5 nM (η-C1B), 7.7 nM (ε-C1B), 8.3 nM (δ-C1B), 18.9 nM (β-C1A-long), 20.8 nM (α-C1A-long), 137 nM (β-C1B), 138 nM (γ-C1A), 213 nM (γ-C1B), respectively[2]. (-)-Indolactam V (20 nM-5 μM) dose-dependently affects multiple hESC lines, such as HUES 2, 4 and 8. (-)-Indolactam V also increases the mRNA levels of Pdx1, HNF6, PTF1A, SOX9, HB9 and PROX1. In addition, (-)-Indolactam V (300 nM) functions in both mouse and human cells and confirms that some signals for pancreatic development[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

301.38

Formula

C17H23N3O2

CAS 号

90365-57-4

中文名称

吲哚内酰胺 V

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (165.90 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.3181 mL 16.5904 mL 33.1807 mL
5 mM 0.6636 mL 3.3181 mL 6.6361 mL
10 mM 0.3318 mL 1.6590 mL 3.3181 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (8.30 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.30 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (8.30 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.30 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (8.30 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.30 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Nakagawa Y, et al. Synthesis and biological activities of indolactone-V, the lactone analogue of the tumor promoter (-)-indolactam-V. Biosci Biotechnol Biochem. 1997 Aug;61(8):1415-7.

    [2]. Masuda A, et al. Binding selectivity of conformationally restricted analogues of (-)-indolactam-V to the C1 domains of protein kinase C isozymes. Biosci Biotechnol Biochem. 2002 Jul;66(7):1615-7.

    [3]. Chen S, et al. A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nat Chem Biol. 2009 Apr;5(4):258-65.

Cell Assay
[3]

For induced differentiation to endocrine or exocrine cells, the (-)-Indolactam V (300 nM)-treated populations are cultured in DMEM/F12 supplemented with 1 N2, 2 mg/mL albumin fraction V and 10 ng/mL bovine FGF for the first 4 d. 10 mM nicotinamide is then added and maintained for an additional 8 d, changing the medium every 3 d[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Nakagawa Y, et al. Synthesis and biological activities of indolactone-V, the lactone analogue of the tumor promoter (-)-indolactam-V. Biosci Biotechnol Biochem. 1997 Aug;61(8):1415-7.

    [2]. Masuda A, et al. Binding selectivity of conformationally restricted analogues of (-)-indolactam-V to the C1 domains of protein kinase C isozymes. Biosci Biotechnol Biochem. 2002 Jul;66(7):1615-7.

    [3]. Chen S, et al. A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nat Chem Biol. 2009 Apr;5(4):258-65.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务